Member Info for pomander

Bignose -as it serves no purpose for RP to delay matters, 'maybe' we are being too harsh on RP. The RNS to which you refer in 2014 Q1 was in reference to the NDA Guidance meeting. RP submitted a Registration Study PE-008 to the FDA in Nov 2014 (10 months later). Then there was a big gap of 16 months before the scope of the PRO (Patient Reported Outcomes) was submitted to approval with FDA. The clinical readouts from the PRO's 008 is not expected until 2018 Q1 for part 1 and 2019 Q2 - part 2. I don't know if the 16 omonth delay was down to RP or simply the speed at which the FDA operates- I suspect the latter. It seesm to me that when the original realse was made in 2014 Q1 that RP did not understand what lay ahead nor the time frame to complete. Perhaps they were caight out by FDA requiring further stuf dies rather than a rubber stamping of the EMA approval. In teh absence of any information to the contrary, I presume the 20 dose can is stil the plan, so that does not seem to be the linked to the delay.

Its not te spray mechanism as such that is the USP but the copound as a alternative to direct injection which is only alternative for no reponders to Viagra/Cialis. This will hopefully provide you with info you are seeking. http://www.regentpac.com/ICMServlet/download/18-2154-3507/(1F)CompanyOverview-RPGL(October2017)-English.pdf

Bignose - You cannot really put the FDA delay down to the production issues for EU launch as MW confirmed to me that extensive & expensive market research in the US had shown that a 20 dose cannister was the optimum size. Now unless that all changed for some reason there was no need as you say to delay the US launch - don't think we have all the facts?

Bignose- from what I can sniff, Preboost is just another of many inferior monograph products. Alq also did not mention that clinical data whilst latency time increased, it also showed sexual satisfaction decreased, although that would not of course figure in the press release. So don't think US presribers will be getting too exercised about recommending it, any more than for other monograpg products. Timm would also seem to be a company of limited resources, with little or no marketing money to throw at this, and a field network not as comprehensive as Alq would seem to beleive. Seems to me there is a huge potential market with a number of small players tinkering at the edges. A major player with the first FDA approved product to offer might be a very attractive commercial proposition.

It is correct. In medical terminology, an "indication" for a drug refers to the use of that drug for treating a particular disease. For example, diabetes is an indication for insulin.

I'll say the clinical data was thin -The PREBOOST� Clinical Study enrolled 26 men aged 18 years or older in a heterosexual, monogamous relationship, with PE That's about as thin as tin can be!!! Good to see they agree with my view on antodepressants and PDE-5 inhibitors There are no prescription products for PE approved by the United States FDA. Off-label use of antidepressants and PDE-5 inhibitors have been used with limited success because of inconsistent efficacy and unacceptable side effects. Psychological counseling and behavioral therapy are also used with mixed results. Of the consumer health products, the topical anesthetics are administered as sprays and gels Veru Inc also mentions and on the same lines as your comments-Of the consumer health products, the topical anesthetics are administered as sprays and gels. The drawbacks of these approaches include inconsistent dosing leading to too much anesthetic and transference of the anesthetics to the partner. I guess men can use a baby wipe but not a spray, and one that has been approved.

Bignose- Ple aquired Timms for US$9.5m back in 2006. Ple run into debt and funding issues so it divetsed Timms in 2009 and also around that time did the deal with Shiongi to reduce it debt and financing issues. Timms was acquired by Actienet Pharma in 2011, so either retained trading nbame or moree coprporate activity - but I am losing the scent to sniff any further! So in this case there is no resurrection and no second coming. Timms has just launched in the US Proboost which is a baby wipe to numb your Rodger, although not recommended for use as hankerchief for those nosey enough to try.

I think Ple was underfunded and going nowwhere until JM recognised potential and got stuck in. He closedn the urolgy dept to focus on PSD 502 only, break the arrangement with Shingoi and clear out the likes of Alq - only joking Alq! Timm Medical Tech - now that really is a top sniff - they have rcently announced an agreemenet with Veru Inc to distribute and to promote Preboost for prevention of premature ejaculation. https://globenewswire.com/news-release/2017/10/03/1140113/0/en/Veru-Inc-Announces-Agreement-with-Timm-Medical-Technologies-LLC-to-Distribute-and-to-Promote-PREBOOST.html

Apple- I am afraid for AIM stocks the negative view is that the appointmenet of a joint broker is a sign of dilution to follow via a Placing or a BOD that just wants to get high. On balance I would subsribe to this, given the very poor SP performance, N=1 Singer maybe struggling to sell the Summ story to its clients. It might also explain the oddly titled RNS - Miscellaneous, almost like they were trying to hide it, wheresas if it were for positive reasons I would have expected more fanfare. Hopefully I am wrong, and it will not be for the first time.

would seem to support selling more than 10 per week and 262 cans as at August 2017. I have tried to get numbers from Chemuist 4 U but they will not divulge. Has anyone contated JG/MW on this? RWL have been at advanced stage for an eternity - now that production issues resolved perhaps they could be announced at any time? Update of FDA submission would also be helpful.

Yes, but why are they selling the 20 dose can at �99.99 rather than teh 5ml 12 dose can at �49.99?

Oddly titled Miscellaneous - hopefully a positive sign

50 day Simple Moving averge technical traders look for short term averages crossing above longer term averages as a signal for the beginning of an uptrend. The gap is reference to the difference between teh 50 SMA and a longer SMA, probably the 200 day SMA. If I have got this wrog I am sure Esco will correct me Of more siginificance to me is that Venturex Resources drove a 8% x 13% = +1.04% rise and yet we were down 3.9% on ribbish volumes again.

Indeed Apple - lets hope for a good outcome.

tinman- he said and to quote 'Not mentioned neither on their website'- which of course the holding is, if you care to take the time to read the announcements. Seems as well as not being able to constrct a sentence that he can 'neither' understand his own postings. He is also making himself look more dumb than ever but seeking to put down JM and Co by refering to a profitable hidden investment - normally investments are hidden when they are in a position of loss. That's the problem when you spend too much time in your bedroom playing Super Mario and trying a get a line of orange on your Rubic Cube whilst mummy calls you down in vain to come and get your dinner.

I have no idea what Sarepta's plans are but it is not uncommon for company's of Summits size to get picked off at prices below shareholders hopes, but that is down to teh real world, raising capital and the low probabilty of getting a drug to market. The war chest is not needed to meet the milestones, stella P2 readouts would take care of that, and that is what I am hoping for, or this could quite easily implode - its approaching a binary point in my view.

Would be a great irony Metal prices and high-grade hits combine to show Venturex�s time has come | Resources Rising Stars http://www.resourcesrisingstars.com.au/news-article/metal-prices-and-high-grade-hits-combine-show-venturex%E2%80%99s-time-has-come �. Regent has a big stake

Good sniff - its circa 12% of the current mkt cap but they want to rebrand as a pharma investment company. It is also subject to Mareva Injunction in connection with the on-going tax dispute. By comparison to the DBC as it currently stands future prospects for Venturex look far better.

I think significance he is alluding to is that HK is a massive market in terms of investor capital compared to little old AIM which is miniscule by comparison and they have relatively few pharma's listed in HK. Two views, post Nov 2016 was first evidence of this mountain of cash or it was evidence of a stakebuilder with HK punters trading around that. I favour the latter theory, only because we have not got anywhere near the 3 billion shares traded post Nov 2016 despite the news flow.

Come on now Alq don't be churlish, the very fact alone that Fortacin has an EMA approval and is seeking FDA approval makes it superior to other products. Reality is not always teseame as perception. Now for a large Bison and tonic - wonderful oily Polish Vodka and very affordable. No booze snobbery form me.